Human DNA topoisomerase IB: Structure and functions

Italian Journal of Biochemistry

Volumn 56, Issue 2, 2007, Pages 91-102

  Cretaio, Erica ^a   Pattarello, Luca ^a   Fontebasso, Yari ^b   Banedetti, Piero ^a   Losasso, Carmen ^a,c  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF SUSSEX   (United Kingdom)

^c Fondazione Adriano Buzzati Traverso   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE;

ARTICLE; CATALYSIS; CHEMISTRY; DNA REPLICATION; DNA SUPERCOILING; GENETIC RECOMBINATION; GENETIC TRANSCRIPTION; HUMAN; METABOLISM; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

CATALYSIS; DNA REPLICATION; DNA TOPOISOMERASES, TYPE I, EUKARYOTIC; DNA, SUPERHELICAL; HUMANS; PROTEIN STRUCTURE, TERTIARY; RECOMBINATION, GENETIC; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION, GENETIC;

EID: 34547652554     PISSN: 00212938     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Wang JC Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol. 2002;3(6):430-40.
2. Leppard JB, Champoux JJ. Human DNA topoisomerase l: relaxation, roles, and damage control. Chromosoma. 2005; 114(2)75-85.
3. Forterre P, Gribaldo S, Gadelle D, Serre MC Origin and evolution of DNA topoisomerases. Biochimie. 2007 Jan 4
4. Staker BL, Feese MD, Cushman M, Pommier Y, Zembower D, Stewart L, Burgin AB. Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J Med Chem. 2005;48(7):2336-45
5. Stewart L, Redinbo MR, Qiu X, Hol WG, Champoux JJ. A model for the mechanism of human topoisomerase I. Science. 1998;279(5356):1534-41.
6. Redinbo MR, Stewart L, Kuhn P, Champoux JJ, Hol WG. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA. Science. 1998;279(5356): 1504-13
7. Stewart L, lreton GC, Champoux JJ. The domain organization of human topoisomerase I. J Biol Chem. 1996 29;271(13):7602-8
8. Stewart L, lreton GC, Parker LH, Madden KR, Champoux JJ. Biochemical and biophysical analyses of recombinant forms of human topoisomerase I. J Biol Chem. 1996;271(13):7593-601
9. Mo YY, Wang C, Beck WT. A novel nuclear localization signal in human DNA topoisomerase I. J Biol Chem. 2000;275(52):41107-13.
10. lreton GC, Stewart L, Parker LH, Champoux JJ. Expression of human topoisomerase I with a partial deletion of the linker region yields monomeric and dimeric enzymes that respond differently to camptothecin.J Biol Chem. 2000 Aug 18;275(33:25820-30.
11. Svejstrup JQ, Christiansen K, Andersen AH, Lund K, Westergaard O. Minimal DNA duplex requirements for topoisomerase I-mediated cleavage in vitro. J Biol Chem. 1990;265(21):12529-35.
12. Busk H, Thomsen B, Bonven BJ, Kjeldsen E, Nielsen OF, Westergaard O. Preferential relaxation of supercoiled DNA containing a hexadecameric recognition sequence for topoisomerase I. Nature. 1987;327(6123):638-40
13. Redinbo MR, Champoux JJ, Hol WG. Novel insights into catalytic mechanism from a crystal structure of human topoisomerase I in complex with DNA. Biochemistry. 2000;39(23):6832-40.
14. Redinbo MR, Champoux JJ, Hol WG. Novel insights into catalytic mechanism from a crystal structure of human topoisomerase I in complex with DNA. Biochemistry. 2000;39(23):6832-40.
15. Yang Z, Champoux JJ. The role of histidine 632 in catalysis by human topoisomerase I. J Biol Chem.2001 ;276(1:677-85.
16. Interthal H, Quigley PM, Hol WG, Champoux JJ. The role of lysine 532 in the catalytic mechanism of human topoisomerase I. J Biol Chem. 2004;279(4:2984-92.
17. Been MD, Burgess RR, Champoux JJ. Nucleotide sequence preference at rat liver and wheat germ type 1 DNA topoisomerase breakage sites in duplex SV40 DNA. Nucleic Acids Res. 1984;12(7):3097-114.
18. Parker LH, Champoux JJ. Analysis of the biased distribution of topoisomerase I break sites on replicating simian virus 40 DNA. J Mol Biol. 1993;231(1):6-18.
19. Stewart L, lreton GC, Champoux JJ. Reconstitution of human topoisomerase I by fragment complementation. J Mol Biol. 1997;269(3):355-72
20. Stewart L, lreton GC, Champoux JJ. A functional linker in human topoisomerase I is required for maximum sensitivity to camptothecin in a DNA relaxation assay. J Biol Chem. 1999;274(46):32950-60
21. Fiorani P, Bruselles A, Falconi M, Chiliemi G, Desideri A, Benedetti P. Single mutation in the linker domain confers protein flexibility and camptothecin resistance to human topoisomerase I. J Biol Chem. 2003 Oct 31;278(44):43268-75
22. Losasso C, Cretaio E, Palle K, Pattarello L, Bjornsti MA, Benedetti P. Alterations in linker flexibility suppress DNA topoisomerase I mutant-induced cell lethality. J Biol Chem. 2007 Mar30;282(13):9855-64.
23. Fiorani P, Amatruda JF, Silvestri A, Butler RH, Bjornsti MA, Benedetti P. Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity. Mol Pharmacol. 1999;56(6):1105-15.
24. Megonigal MD, Fertala J, Bjornsti MA. Alterations in the catalytic activity of yeast DNA topoisomerase I result in cell cycle arrest and cell death. J Biol Chem. 1997;272(19):12801-8.
25. Alsner J, Svejstrup JQ, Kjeldsen E, Sorensen BS, Westergaard O. Identification of an Nterminal domain of eukaryotic DNA topoisomerase I dispensable for catalytic activity but essential for in vivo function. J Biol Chem. 1992;267(18):12408-11.
26. Labourier E, Rossi F, Gallouzi IE, Allemand E, Divita G, Tazi J. Interaction between the Nterminal domain of human DNA topoisomerase I and the arginine-serine domain of its substrate determines phosphorylation of SF2/ASF splicing factor. Nucleic Acids Res. 1998;26(12):2955-62.
27. Lisby M, Olesen JR, Skouboe C, Krogh BO, Straub T, Boege F, Velmurugan S, Martensen PM, Andersen AH, Jayaram M, Westergaard O, Knudsen BR. Residues within the N-terminal domain of human topoisomerase I play a direct role in relaxation. J Biol Chem. 2001;276(23):20220-7.
28. Frohlich RF, Andersen FF, Westergaard O, Andersen AH, Knudsen BR. Regions within the Nterminal domain of human topoisomerase I exert important functions during strand rotation and DNA binding.J Mol Biol. 2004;336(1):93-103.
29. Sari L, Andricioaei I. Rotation of DNA around intact strand in human topoisomerase I implies distinct mechanisms for positive and negative supercoil relaxation. Nucleic Acids Res. 2005;33(20):6621-34.
30. Woo MH, Losasso C, Guo H, Pattarello L, Benedetti P, Bjornsti MA. Locking the DNA topoisomerase I protein clamp inhibits DNA rotation and induces cell lethality. Proc Natl Acad Sci USA. 2003; 100(24): 13767-72.
31. Carey JF, Schultz SJ, Sisson L, Fazzio TG, Champoux JJ. DNA relaxation by human topoisomerase I occurs in the closed clamp conformation of the protein. Proc Natl Acad Sci U S A. 2003;100(10):5640-5.
32. Strick TR, Allemand JF, Bensimon D, Bensimon A, Croquette V. The elasticity of a single supercoiled DNA molecule. Science. 1996;271(5257):1835-7.
33. Strick TR, Allemand JF, Bensimon D, Croquette V. Stress-induced structural transitions in DNA and proteins. Annu Rev Biophys Biomol Struct. 2000;29:523-43.
34. Koster DA, Croquette V, Dekker C, Shuman S, Dekker NH. Friction and torque govern the relaxation of DNA supercoils by eukaryotic topoisomerase IB. Nature. 2005;434(7033):671-4.
35. Baker SD, Wadkins RM, Stewart CF, Beck WT, Danks MK. Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy. Cytometry. 1995; 19(2): 134-45.
36. Larsen AK, Gobert C. DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde? Pathol Oncol Res. 1999;5(3):171-8.
37. Bronstein IB, Vorobyev S, Timofeev A, Jolies CJ, Alder SL, Holden JA. Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies. Oncol Res. 1996;8(1):17-25.
38. Gilmour DS, Pflugfelder G, Wang JC, Lis JT.Topoisomerase I interacts with transcribed regions in Drosophila cells. Cell, 1986; 44(3):401-7
39. Fleischmann G, Pflugfelder G, Steiner EK, Javaherian K, Howard GC, Wang JC, Elgin SC. Drosophila DNA topoisomerase I is associated with transcriptionally active regions of the genome Proc Natl Acad Sci U S A. 1984; 81(22):6958
40. Christensen MO, Barthelmes HU, Boege F, Mielke C The N-terminal domain anchors human topoisomerase I at fibrillar centers of nucleoli and nucleolar organizer regions of mitotic chromosomes. J Biol Chem. 2002;277(39):35932-8
41. Christensen MO, Krokowski RM, Barthelmes HU, Hock R, Boege F, Mielke C. Distinct effects of topoisomerase I and RNA polymerase I inhibitors suggest a dual mechanism ofnucleolar/nucleoplasmic partitioning of topoisomerase I. J Biol Chem. 2004;279(21):21873-82.
42. Merino A, Madden KR, Lane WS, Champoux JJ, Reinberg D. DNA topoisomerase I is involved in both repression and activation of transcription. Nature. 1993;365(6443):227-32.
43. Kretzschmar M, Meisterernst M, Roeder RG. Identification of human DNA topoisomerase I as a cofactor for activator-dependent transcription by RNA polymerase II. Proc Natl Acad Sci U S A. 1993, 15;90(24): 11508-12
44. Shykind BM, Kim J, Stewart L, Champoux JJ, Sharp PA. Topoisomerase I enhances TFIIDTFIIA complex assembly during activation of transcription. Genes Dev. 1997 Feb 1;11(3):397-407
45. Rossi F, Labourier E, Forne T, Divita G, Derancourt J, Riou JF, Antoine E, Cathala G, Brunei C, Tazi J. Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I. Nature. 1996;381(6577):80-2.
46. Rossi F, Labourier E, Gallouzi IE, Derancourt J, Allemand E, Divita G, Tazi J The C-terminal domain but not the tyrosine 723 of human DNA topoisomerase I active site contributes to kinase activity. Nucleic Acids Res. 1998;26(12):2963-70
47. Cheng C, Kussie P, Pavletich N, Shuman S. Conservation of structure and mechanism between eukaryotic topoisomerase I and site-specific recombinases. Cell. 1998;92(6):841-50
48. Wang HP, Rogler CE. Topoisomerase l-mediated integration of hepadnavirus DNA in vitro. J Virol. 1991;65(5):2381-92.
49. Soe K, Hartung S, Grosse F. Human topoisomerase I forms double cleavage complexes on natural DNA. Biochem Biophys Res Commun. 2006;349(1): 178-85.
50. Soe K, Rockstroh A, Schache P, Grosse F. The human topoisomerase I damage response plays a role in apoptosis.DNA Repair (Amst). 2004 Apr 1;3(4):387-93.
51. Pommier Y, Kerrigan D, Hartman KD, Glazer RI. Phosphorylation of mammalian DNA topoisomerase I and activation by protein kinase C. J Biol Chem. 1990;265(16):9418-22
52. Yu D, Khan E, Khaleque MA, Lee J, Laco G, Kohlhagen G, Kharbanda S, Cheng YC, Pommier Y, Bharti A. Phosphorylation of DNA topoisomerase I by the c-Abl tyrosine kinase confers camptothecin sensitivity. J Biol Chem. 2004;279(50):51851-61
53. Rockstroh A, Kleinert A, Kramer M, Grosse F, Soe K. Cellular stress triggers the human topoisomerase I damage response independently of DNA damage in a p53 controlled manner.Oncogene. 2007;26(1):123-31
54. Soe K, Grosse F. p53 stimulates human topoisomerase I activity by modulating its DNA binding. Nucleic Acids Res. 2003 Nov 15;31(22):6585-92
55. Stephan H, Grosse F, Soe K. Human topoisomerase I cleavage complexes are repaired by a p53-stimulated recombination-like reaction in vitro Nucleic Acids Res. 2002 Dec 1;30(23):5087-93
56. Ferro AM, Olivera BM. Poly(ADP-ribosylation) of DNA topoisomerase I from calf thymus. J Biol Chem. 1984;259(1):547-54
57. Lynch BJ, Bronstein IB, Holden JA. Elevations of DNA topoisomerase I in invasive carcinoma of the breast. Breast J. 2001 ;7(3): 176-80
58. Coleman LW, Perkins SL, Bronstein IB, Holden JA. Expression of DNA toposiomerase I and DNA topoisomerase II-alpha in testicular seminomas.Hum Pathol. 2000;31(6):728-33.
59. Monnin KA, Bronstein IB, Gaffney DK, Holden JA. Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression. Hum Pathol. 1999;30(4):384-91
60. Staley BE, Samowitz WS, Bronstein IB, Holden JA. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon. Mod Pathol. 1999;12(4):356-61
61. Holden JA, Rahn MP, Jolles CJ, Vorobyev SV, Bronstein IB. Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas. Mol Pathol. 1997;50(5):247-53
62. Gupta D, Bronstein IB, Holden JA. Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival. Hum Pathol. 2000;31(2):214-9.
63. Pommier Y., Topoisomerase I Inhibitors: Molecular and Cellular Determinants of Activity. http://discover.nci.nih.gov/pommier/top1.htm, updated October 2003.
64. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985;260(27):14873-8
65. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res. 2002;8(3):641-61.
66. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB Jr, Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci USA. 2002;99(24):15387-92
67. Larsen AK, Skladanowski A. Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death. Biochim Biophys Acta. 1998;400(13):257-74 68 Li TK, Liu LF. Tumor cell death induced by topoisomerase-targeting drugs. Annu Rev Pharmacol Toxicol. 2001;41:53-77 69 Sordet O, Khan QA, Kohn KW, Pommier Y. Apoptosis induced by topoisomerase inhibitors. Curr Med Chem Anticancer Agents. 2003;3(4):271-90
68. Chrencik JE, Staker BL, Burgin AB, Pourquier P, Pommier Y, Stewart L, Redinbo MR. Mechanisms of camptothecin resistance by human topoisomerase I mutations. J Mol Biol. 2004;339(4):773-84
69. Reid RJ, Benedetti P, Bjornsti MA. Yeast as a model organism for studying the actions of DNA topoisomerase-targeted drugs. Biochim Biophys Acta. 1998; 1400(1-3):289-300.